I think there are two aspects:
We know from the November AGM they are looking at Melanoma and ccRCC, but we also know from the November 2020 preclinical Breast Cancer announcement that they have been doing further studies looking at FTO and Breast Cancer (3 months is probably enough time to get some results in-vitro).
- The performance of the drug for inhibiting FTO and hence killing or slowing the growth of cancer cells. This means testing Bisantrene in-vitro both individually and in combination with other cancer drugs ( e.g. Keytruda or Opdivo ).
- Determining the biomarkers / tests required for each targeted cancer type to aid in diagnosis of individuals with the genetic traits where inhibiting FTO will help with treatment of their cancer.
There are likely other biomarkers relevant to each cancer. For example biomarkers related to the VHL gene for ccrCC.
I think there could be up to six areas where we could get preclinical results:
I'm leaning towards an announcement focused on FTO and Breast Cancer ( #1, #2 ) since it's confirmed from the November 2020 announcement they were doing further preclinical study on FTO and Breast Cancer. It's also logically a priority given they priority they have on a Breast Cancer trial ( there may be data they want to capture or it may inform their trial plans ).
- Significance of FTO for Breast Cancer and testing of drug combinations
- Relevant biomarkers for FTO and Breast Cancer
- Testing of Bisantrene as a single agent and in drug combinations for Melanoma
- Relevant biomarkers for FTO and Melanoma
- Testing of Bisantrene as a single agent and in drug combinations for ccRCC
- Relevant biomarkers for FTO and ccRCC
I think there will be newsflow on #3 to #6 later in the year.
- Forums
- ASX - By Stock
- RAC
- The RAC 3-Pillar Trifecta
The RAC 3-Pillar Trifecta, page-413
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.010(0.60%) |
Mkt cap ! $287.1M |
Open | High | Low | Value | Volume |
$1.69 | $1.70 | $1.65 | $89.01K | 53.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | 1.685 |
1 | 3664 | 1.680 |
1 | 5077 | 1.660 |
1 | 1265 | 1.650 |
1 | 612 | 1.635 |
Price($) | Vol. | No. |
---|---|---|
1.695 | 5 | 1 |
1.700 | 11000 | 1 |
1.730 | 2399 | 1 |
1.750 | 952 | 2 |
1.775 | 1328 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online